Biomarker testing for people with advanced lung cancer in England
Adizie, Jana B Tweedie, Judith Khakwani, Aamir Peach, Emily Hubbard, Richard Wood, Natasha Gosney, John R Harden, Susan V Beckett, Paul Popat, Sanjay
Adizie, Jana B
Tweedie, Judith
Khakwani, Aamir
Peach, Emily
Hubbard, Richard
Wood, Natasha
Gosney, John R
Harden, Susan V
Beckett, Paul
Popat, Sanjay
Citations
Altmetric:
Affiliation
University Hospitals Birmingham NHS Foundation Trust; Belfast Health and Social Care Trust; University of Nottingham; Nottingham University Hospitals NHS Trust; Public Health England; Royal Liverpool University Hospital; Monash University; University Hospitals of Derby and Burton NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University College London
Other Contributors
Publication date
2021-04-27
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England.
Methods: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information.
Results: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy.
Conclusions: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved.
Citation
Adizie JB, Tweedie J, Khakwani A, Peach E, Hubbard R, Wood N, Gosney JR, Harden SV, Beckett P, Popat S, Navani N. Biomarker Testing for People With Advanced Lung Cancer in England. JTO Clin Res Rep. 2021 Apr 27;2(6):100176. doi: 10.1016/j.jtocrr.2021.100176.
Type
Article